ATE125626T1 - Cytokeratin-tumormarkierer und test zu deren nachweis. - Google Patents

Cytokeratin-tumormarkierer und test zu deren nachweis.

Info

Publication number
ATE125626T1
ATE125626T1 AT85900840T AT85900840T ATE125626T1 AT E125626 T1 ATE125626 T1 AT E125626T1 AT 85900840 T AT85900840 T AT 85900840T AT 85900840 T AT85900840 T AT 85900840T AT E125626 T1 ATE125626 T1 AT E125626T1
Authority
AT
Austria
Prior art keywords
test
detection
neoplastic
tumor marker
cytokeratin
Prior art date
Application number
AT85900840T
Other languages
English (en)
Inventor
Robert D Cardiff
Paul V Rossitto
Alan C Brabon
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24273031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE125626(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE125626T1 publication Critical patent/ATE125626T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Eye Examination Apparatus (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT85900840T 1984-01-06 1985-01-03 Cytokeratin-tumormarkierer und test zu deren nachweis. ATE125626T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56886284A 1984-01-06 1984-01-06

Publications (1)

Publication Number Publication Date
ATE125626T1 true ATE125626T1 (de) 1995-08-15

Family

ID=24273031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT85900840T ATE125626T1 (de) 1984-01-06 1985-01-03 Cytokeratin-tumormarkierer und test zu deren nachweis.

Country Status (7)

Country Link
US (1) US4775620A (de)
EP (1) EP0167616B1 (de)
JP (5) JP2723203B2 (de)
AT (1) ATE125626T1 (de)
CA (1) CA1336171C (de)
DE (1) DE3588043T2 (de)
WO (1) WO1985003132A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR850552B (de) * 1984-03-07 1985-07-05 Du Pont
AU7144787A (en) * 1986-04-17 1987-10-22 Hybritech Inc. Tumor-associated antigen (mol wt 68,000-48000; 40,000-80000; 28000-32000; 16000-19000)
AU7145087A (en) * 1986-04-17 1988-10-13 Hybritech Inc. Tumor-associated antigens (mol wt 160,000-170,000; 44,000-46,000; 29,000-35,000)
FR2606034B1 (fr) * 1986-10-31 1989-06-02 Cird Nouvelle proteine de surface des cellules basales de l'epiderme, anticorps capables de reconnaitre cette proteine, et leur utilisation, et lignees cellulaires hybrides capables de secreter de tels anticorps
FR2606033B1 (fr) * 1986-10-31 1988-12-16 Cird Proteine cytoplasmique des cellules suprabasales de l'epiderme, anticorps capables de reconnaitre cette proteine, et lignees cellulaires hybrides capables de secreter de tels anticorps
US5660994A (en) * 1986-11-10 1997-08-26 Progen Biotechnik Gmbh Method of detecting tissue-specific, insoluble cytoskeletal proteins
DE3815932A1 (de) * 1988-01-26 1989-08-03 Progen Biotechnik Gmbh Verfahren zur identifizierung des ursprungs einer zellgewebsprobe
DE3923951A1 (de) * 1989-07-19 1991-01-31 Boehringer Mannheim Gmbh Verfahren zum nachweis von leberzirrhose
US5411868A (en) * 1989-10-24 1995-05-02 Board Of Regents, The University Of Texas System Diagnostic and premonitoring uses of a 65 kDa tumor-associated protein in companion and domestic animal malignancy
DE3942999C2 (de) * 1989-12-27 1997-12-18 Progen Biotechnik Gmbh Verfahren zum Nachweis von malignen Erkrankungen
DE4023945A1 (de) * 1990-07-27 1992-01-30 Progen Biotechnik Gmbh Verfahren zur reinigung von cytokeratin 20 und dessen verwendung zur erzeugung von antikoerpern
SE470273B (sv) * 1990-09-24 1993-12-20 Idl Immunodeveloplab Ab Cytokeratinfragment, deras framställning och användning, framställning av monoklonala antikroppar och testkit för epitelialcancer
US5547928A (en) * 1993-12-17 1996-08-20 Matritech, Inc. Methods and compositions for the detection of colon cancers
SE9500023L (sv) * 1994-05-17 1995-11-18 Beki Ab Sätt att detektera cancer
US5914238A (en) 1996-06-05 1999-06-22 Matritech, Inc. Materials and methods for detection of breast cancer
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
US6890311B2 (en) 1997-09-16 2005-05-10 The Regents Of The University Of California Methods for performing medical procedures within a breast duct
US6168779B1 (en) * 1997-09-16 2001-01-02 The Regents Of The University Of California Methods and kits for identifying ductal orifices
BR9907852A (pt) 1998-02-12 2000-10-24 Immunivest Corp Processos para detectar e enumerar células raras e cancerosas em uma população celular mista, para diagnosticar câncer de estágio precoce em um paciente de teste, para determinar a probabilidade de recorrência de câncer em um paciente humano anteriormente tratado de câncer, para distinguir um carcinoma confinado ao órgão de um carcinoma com propriedades metastáticas, para acompanhar a situação de remissão em um paciente humano com câncer que passa pelo tratamento de terapia contra o câncer e para aumentar quantidades de células epiteliais circulantes em uma amostra de sangue, partìcula magnética revestida, composição, conjuntos de teste para avaliar uma amostra de paciente quanto a presença de células raras circulantes, quanto a presença de células de tumor circulantes, quanto a presença de células de câncer de mama circulantes, quanto a presença de células de câncer de próstata circulantes, quanto a presença de células de câncer de cólon circulantes, quanto a presença de células de câncer de bexiga circulantes e para monitorar um paciente quanto a recorrência de câncer, e, fração de sangue periférico enriquecido quanto a células neoplásticas circulantes
GB9905817D0 (en) * 1999-03-12 1999-05-05 Oxford Glycosciences Uk Ltd Methods
ES2274781T3 (es) * 1999-04-13 2007-06-01 Wilex Ag Empleo diagnostico y terapeutico de anticuerpos contra el receptor de la urocinasa.
EP1208381A2 (de) * 1999-08-13 2002-05-29 Oxford GlycoSciences (UK) Limited Verfahren zum nachweis von brustkrebs
WO2001046697A2 (en) * 1999-12-21 2001-06-28 Millennium Predictive Medicine Identification, assessment, prevention, and therapy of breast cancer
GB0004576D0 (en) * 2000-02-25 2000-04-19 Oxford Glycosciences Uk Ltd Proteins
DE10130985B4 (de) * 2001-06-27 2004-03-18 B.R.A.H.M.S Ag Verfahren zur Diagnose von Sepsis und schweren Infektionen unter Bestimmung löslicher Cytokeratin-1-Fragmente
EP1430090A4 (de) 2001-08-31 2006-10-11 Keratec Ltd Herstellung von film-, folien-, faser-, schaumstoff- und klebstoff-biopolymermaterialien aus löslichen s-sulfonierten keratinderivaten
US20030138425A1 (en) * 2001-09-21 2003-07-24 Mather Jennie Powell Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
US7630403B2 (en) * 2002-03-08 2009-12-08 Texas Instruments Incorporated MAC aggregation frame with MSDU and fragment of MSDU
US7297342B2 (en) * 2002-06-10 2007-11-20 Keratec Limited Orthopaedic materials derived from keratin
BR0316793A (pt) * 2002-11-28 2005-11-01 Keratec Ltd Formulações de cuidado pessoal contendo queratina
WO2005028560A1 (en) * 2003-09-19 2005-03-31 Keratec Limited Composite materials containing keratin
EP1698899A4 (de) * 2003-10-30 2007-05-23 Sysmex Corp Diagnostikum für uterusdrüsenkrebs und verfahren zum nachweis einer drüsenkrebszelle
EA011388B1 (ru) * 2003-12-19 2009-02-27 Кератек Лимитед Продукты для ухода за ранами, содержащие кератин
US7579317B2 (en) * 2005-03-11 2009-08-25 Keratec, Ltd. Nutraceutical composition comprising soluble keratin or derivative thereof
WO2008029251A2 (en) * 2006-09-07 2008-03-13 Universitatsklinikum Hamburg-Eppendorf Method for the detection of cancerous epithelial cells using released cytokeratins as markers for said cells
AU2007328181A1 (en) * 2006-12-06 2008-06-12 Keratec, Ltd. Bone void fillers and methods of making the same
AU2007332757A1 (en) * 2006-12-11 2008-06-19 Keratec, Ltd. Porous keratin construct and method of making the same
WO2008148109A1 (en) * 2007-05-24 2008-12-04 Keratec, Ltd. Porous keratin constructs, wound healing assemblies and methods using the same
MX2010004687A (es) * 2007-10-31 2011-03-01 Keraplast Tech Ltd Derivados de queratina y metodos de hacer los mismos.
US11090394B1 (en) 2012-03-27 2021-08-17 Florida A&M University Modified nanodelivery system and method for enhanced in vivo medical and preclinical imaging

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4150149A (en) * 1976-11-29 1979-04-17 Professional Staff Association Of The Los Angeles County Harbor General Hospital Method and means for the early detection and diagnosis of certain types of cancers
US4229426A (en) * 1978-02-22 1980-10-21 Duke University, Inc. Breast cyst fluid protein assay
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
CA1190853A (en) * 1981-10-13 1985-07-23 Roberto L. Ceriani Method and compositions for carcinoma diagnosis
ATE56046T1 (de) * 1983-03-04 1990-09-15 Health Research Inc Monoklonale antikoerper gegen humane brustkarzinomzellen und ihre verwendung in der diagnose und therapie.

Also Published As

Publication number Publication date
WO1985003132A1 (en) 1985-07-18
EP0167616A1 (de) 1986-01-15
JPH10123138A (ja) 1998-05-15
JP2723203B2 (ja) 1998-03-09
EP0167616A4 (de) 1986-09-04
EP0167616B1 (de) 1995-07-26
JPH0681760B2 (ja) 1994-10-19
US4775620A (en) 1988-10-04
DE3588043D1 (de) 1995-08-31
JP2617289B2 (ja) 1997-06-04
JPS61501048A (ja) 1986-05-22
JPS6447392A (en) 1989-02-21
CA1336171C (en) 1995-07-04
JP2537539B2 (ja) 1996-09-25
JP2896362B2 (ja) 1999-05-31
JPH08275778A (ja) 1996-10-22
JPS6452800A (en) 1989-02-28
DE3588043T2 (de) 1996-03-21

Similar Documents

Publication Publication Date Title
ATE125626T1 (de) Cytokeratin-tumormarkierer und test zu deren nachweis.
BR9916207A (pt) Composições e métodos para terapia e diagnósticode câncer ovariano
ATE410446T1 (de) Zusammensetzungen zur behandlung und diagnose von eierstockkrebs
BR0008709A (pt) Método para diagnosticar diferencialmente emonitorar carcinomas malignos de mama
DK0617124T3 (da) Immunreaktivitet overfor udtrykte aktiverede onkogener til diagnose og behandling af maligne svulster
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
DE3682780D1 (de) Mittel fuer die diagnose, die abbildung, die lokalisierung oder die behandlung von tumoren.
NO830570L (no) Antistoffer og antigener for diagnose og behandling av cancer
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização
ES2101695T3 (es) Haptoglobina relacionada con el cancer (hpr).
ES2033823T3 (es) Ensayo en cuanto a cancer de mama humano.
ATE38521T1 (de) Neues protein (pp13), verfahren zu seiner anreicherung und gewinnung sowie seine verwendung.
ATE71225T1 (de) Verwendung eines spezifischen tumorassoziierten antigens, sialosyllactotetraose, in diagnoseoder therapieverfahren bezueglich krebskrankheiten.
BR0111024A (pt) Composições e métodos para a terapia e diagnóstico de câncer de mama
Tosca et al. Antigenic alterations in tumors of epidermal origin
DE69942637D1 (de) Zusammensetzungen und verfahren für die therapie und diagnose von ovariumkrebs
JPS5686194A (en) Novel protein and its manufacture
ATE61734T1 (de) Verwendung eines spezifischen karzinomassoziierenden antigens (hapten), fucosylsialosylgangliotetrose (fuc-gm1) in diagnostischen und therapeutischen verfahren betreffend den menschlichen lungenkrebs (carcinomas von kleinen zellen).
Cannon et al. Expression of tumour-associated antigens in breast cancer primary tissue compared with serum levels
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου
DE3070210D1 (en) A process for preparing tumor antidotes (oncoclasines) from the excrements of goats
IT7830722A0 (it) Metodo di prova in vitro per la diagnosi di tumori maligni.
Mooney et al. Intermediate filament expression in carcinoid tumours
KURENUMA et al. A case report of ameloblastic fibroma Radiographic observation for 3 years and 8 months
Morales In Vitro Generation of Cytotoxic Lymphocytes by Tumor Extracts of Transitional

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time